UPDATE: Stifel Nicolaus Raises PT on Santarus Following GI Physician Survey
June 10, 2013 at 09:34 AM EDT
In a report published Monday, Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Santarus (NASDAQ: SNTS ), and raised the price target from $22.00 to $24.00. In the report, Stifel Nicolaus noted, “With Uceris (induction of remission, active mild-moderate ulcerative colitis/UC) several months into launch, we surveyed 30
